Tweet
I am a graduate student in the Chinese University of Hong Kong. 
-
Marco -
Hi, I am a graduate student in the University of Hong Kong.
Are you still working in NGS? -
Nice to meet you Y Y Leung.
Yes. You can contact me for more.MarcoComment
-
Hi Marco,
What specific area of NGS are you working in? and also may i ask what dept you are from?
I am in the engineering side.
Regards,
Y.Y.Comment
-
Dear Y Y Leung,
Biochemistry. I am doing research on human genome using Solexa. I suppose you are working on algorithm in read mapping? or similar things?MarcoComment
-
Dear Marco,
I am working on data analysis mainly. I am just a new starter. But I guess I would be working on RNA-seq and targetted sequencing these two areas.
I think I would be playing with algorithms. What software are you using?
FannyComment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...Today, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment